Keratoderma, Palmoplantar, Diffuse Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Keratoderma, Palmoplantar, Diffuse. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Keratoderma, Palmoplantar, Diffuse receives a directional strategic score of 73/100, combining unmet need (86/100), competitive intensity (43/100, where higher means more competition) and market attractiveness (69/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

An autosomal dominant disorder characterized by a widely distributed, well-demarcated hyperkeratosis of the palms and soles. There is more than one genotypically distinct form, each of which is clinically similar but histologically distinguishable. Diffuse palmoplantar keratoderma is distinct from palmoplantar keratoderma (KERATODERMA, PALMOPLANTAR), as the former exhibits autosomal dominant inheritance and hyperhidrosis is frequently present.

The reproducible entity is Patsnap disease ID ce30b8c95d534657b80b13a64e685287 with MeSH identifier D015776. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database

DISCUSSION The current literature is extremely limited in its epidemiologic analysis of oMMP, with case studies comprising the bulk of the publications due to the rarity of the condition. Larger studies, mainly based out of Europe, have indicated varying incidence rates of 1 in 12,000 to 1 in 60,000 with no reports on prevalence [20, 21]. One study focused on the incidence and prevalence of oMMP in Colombia utilising the national health registry, and reported an average incidence of 0.24 per 1,000,000 individuals and an average prevalence of 0.22 per 1,000,000 [22]. The use of TriNetX limited to the population in the US allows for a culturally diverse group for analysis, despite the rarity of the condition, and a larger sample size for a more robust assessment of the incidence and prevalence results. Our study found an increasing incidence and prevalence across the 11-year period, which could not only be attributed to rising cases of the disease but also increased awareness of its presentation, stronger data collection, and overall better diagnosis. The treatment of oMMP is focused on halting the progression of fibrosis and controlling inflammation [3]. Systemic immuno­ suppressive drug therapy is the gold standard as topical treatment alone is insufficient and ineffective [23]. The choice of therapy often depends on the disease stage and severity. Most patients present with moderate to advanced disease, requiring aggressive treatment with biologics (such as rituximab) or 3260

Review the epidemiology source

Epidemiology evidence 2: Recent global patterns in skin cancer incidence, mortality, and prevalence

tions to 2040. JAMA Dermatol 2022;158:495–503. doi: 10.1001/ jamadermatol.2022.0160. 14. Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cuta- neous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol 2014;28:1170–1178. doi: 10.1111/jdv.12236. 15. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemi- ology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107:119–126. doi: 10.1002/ijc.11360. 16. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (Keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015;151:1081– 1086. doi: 10.1001/jamadermatol.2015.1187. 17. Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin 2012;30:355–361. doi: 10.1016/j. det.2012.04.001. 18. Cakir BÖ, Adamson P, Cingi C. Epidemiology and economic bur- den of nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2012;20:419–422. doi: 10.1016/j.fsc.2012.07.004. 19. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr., Gold- man ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425–429. doi: 10.1067/mjd.2003.186. 20. Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol 2020;156:57–64. doi: 10.1001/jamaderma

Review the epidemiology source

Epidemiology evidence 3: Incidence, prevalence, and mortality of localized scleroderma in Quebec, Canada: a population-based study Incidence,prevalence,andmortalityoflocalizedsclerodermainQuebec, Canada: a population-based study

1 Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64:217–228. 2 Pérez M, Zuccaro J, Mohanta A, et al. Feasibility of using elastog- raphy ultrasound in pediatric localized scleroderma (morphea). Ultrasound Med Biol. 2020;46:3218–3227. 3 Mahmood F, Nguyen A, Muntyanu A, et al. Prevalence and inci- dence of localized scleroderma: a qualitative systematic review. J Cutan Med Surg. 2022;26:632–633. 4 Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cu- mulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–173. 5 von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296. 6 Government of Canada, Canada S. Population and dwelling counts: Canada, provinces and territories. https://www150.statcan.gc.ca/t1/ tbl1/en/tv.action?pid=9810000101; 2022. Accessed January 25, 2024. 7 La RAMQ en quelques chiffres. https://www.ramq.gouv.qc.ca/en/ node/89526. Accessed May 17, 2023. 8 Bernatsky S, Dekis A, Hudson M, et al. Rheumatoid arthritis prevalence in Quebec. BMC Res Notes. 2014;7:937. 9 Shiff NJ, Lix LM, Joseph L, et al. The prevalence of systemic auto- immune rheumatic diseases in Canadian pediatric populations: administrative database estimates. Rheumatol Int. 2015;35:569–573. 10 Muntyanu A, Milan R, Kaouache M, et al. Tree-based machine learning to identify predictors of psoriasis incidence at the neigh- borho

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Keratoderma, Palmoplantar, Diffuse, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Keratoderma, Palmoplantar, Diffuse thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor is COL1A1. It is a pathway hypothesis, not a claim that every Keratoderma, Palmoplantar, Diffuse patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 2 registered studies. Recent sampled records include:

• NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies; Not yet recruiting; Phase 1/2; sponsor Northwestern University, Yale University; enrollment 44.
• JPRN-UMIN000036336 — Analysis of sweating response after thermal stimulus; Recruiting; Not Applicable; sponsor Kawasaki Medical School; enrollment 100.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate COL1A1 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Keratoderma, Palmoplantar, Diffuse merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if COL1A1 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Keratoderma, Palmoplantar, Diffuse is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.